Meeting
2016 ASCO Annual Meeting
A phase 1 study of bevacizumab in combination with niraparib in patients with platinum-sensitive epithelial ovarian cancer: The ENGOT-OV24/AVANOVA1 trial.
Authors
Mansoor Raza Mirza
The Finsen Center Department of Oncology, Ballerup, Denmark
Mansoor Raza Mirza , Christiane Ehlers Mortensen , Rene dePont Christensen , Louise Christoffersen , Mia Westergaard , Louisa Boufercha , Michael Birrer , Elisabeth Avall-Lundqvist , Line Bjorge , Johanna Unelma Maenpaa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT02354131
Citation
J Clin Oncol 34, 2016 (suppl; abstr 5555)
DOI
10.1200/JCO.2016.34.15_suppl.5555
Abstract #
5555
Poster Bd #
378
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.
First Author: Judith Michels
Poster
2019 ASCO Annual Meeting
A phase I study of veliparib incorporated into front-line platinum based cheotherpy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial.
First Author: Deborah Kay Armstrong
Poster
2015 ASCO Annual Meeting
ENGOT-OV24-NSGO/AVANOVA: Niraparib versus bevacizumab-niraparib combination versus bevacizumab and niraparib as sequential therapy in women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
First Author: Mansoor Raza Mirza
Poster
2015 ASCO Annual Meeting
A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies.
First Author: Rana R. McKay